This past fall, the National Institutes of Health, the Food and Drug Administration and other partners launched the Bespoke Gene Therapy Consortium in an effort to leverage adeno-associated viruses as vectors to treat rare diseases. The initiative seeks to streamline research to clinical use, driving efficiencies into the traditional research and development process. FDA leader Peter Marks and NIH’s P.J. Brooks discuss the consortium’s work and how it aims to help people with rare diseases.
HealthCast
Season 2
Episode 39
21m listen
Gene Therapy is Fighting Rare Diseases in FDA, NIH Program
The technique aims to treat some diseases by gene replacement.
-
Dr. Peter Marks Director CBER, FDA -
P.J. Brooks Deputy Director, Office of Rare Diseases Research NCATS, NIH
Related Content
-
DHS Leads Government’s Largest Civilian AI Hiring Effort
On this AI GovCast miniseries, Boyce discusses his journey to the agency with his prior roles at the Office of Management and Budget.
15m listen -
Storytelling Miniseries: Using Narratives to Nurture Relationships
In the final episode of our Storytelling Miniseries, we discuss building meaningful relationships through storytelling.
20m listen -
How AI Improves Decision-Making and Workload at Borders
Customs and Border Protection CTO Sunil Madhugiri discussed how the agency is using artificial intelligence at the nation’s borders.
19m listen -
Quantum, Workforce Issues Lead FDA’s Digital Transformation
The FDA is taking a proactive approach to its digital transformation efforts that its tech leaders highlighted in a new IT strategy.
14m listen
